Table 3.

Clinical characteristics of patients with AIH before tacrolimus treatment

Patient	Gender	Age	Prednisolone	Additional	HLA type	ALT	IgG	INR	Bilirubin	Albumin	Creatinine	Follow-up
No.		(yr)	dose	immonusupression		(U/L)	(g/L)		(μmol/L)	(g/L)	(μmol/L)	(mo)
1	F	64	20	MMF	N.A.	271	15	1.1	9	37.8	88	37
2	F	32	20	AZA	DR-3	156	29	1.6	30	28.0	71	20
3	F	49	20	MMF	DR-4,15	109	18	1.1	13	34.7	85	34
4	F	20	40	AZA	N.A.	102	12.3	0.9	13	43.0	55	18
5	F	17	20	AZA	DR-17, DQ2	475	30.2	1.0	146	39.1	59	13
6	M	16	80	AZA	DR-7,17	154	16	1.5	8	37.1	65	17
7	F	55	25	AZA	DR-4,13	100	17	1.1	58	37.1	49	12
8	F	49	20	AZA	DR-4,7	202	10	1.2	15	42.2	66	12
9	F	32	20	MMF	N.A.	126	16	1.1	6	33.3	68	36